Glaukos (GKOS)
(Delayed Data from NYSE)
$82.10 USD
-0.25 (-0.30%)
Updated Sep 17, 2025 04:00 PM ET
After-Market: $82.17 +0.07 (0.09%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth D Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
GKOS 82.10 -0.25(-0.30%)
Will GKOS be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for GKOS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GKOS
Glaukos Builds Dual Growth Engines Amid Market Headwinds
GKOS Stock Falls Despite Q2 Earnings & Revenues Beat, Guidance Raised
GKOS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Glaukos (GKOS) Reports Q2 Loss, Tops Revenue Estimates
Glaukos Ramps Up iDose TR, Battles Legacy and Reimbursement Risks
What Makes Glaukos (GKOS) a New Buy Stock
Other News for GKOS
Needham medtech & diagnostics analysts hold analyst/industry conference call
Is GKOS ready to move higher? Stochastic Buy Signal shows up after gaining 2.12%
Needham medtech & diagnostics analysts hold analyst/industry conference call
Glaukos (GKOS) Gains Positive Attention from Stifel Analyst
Stifel sees opportunity in Glaukos selloff, adds to Select List